Spero Therapeutics Inc

NASDAQ:SPRO  
13.97
+1.00 (+7.71%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)445.10M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.53 Million
Adjusted EPS-$0.73
See more estimates
10-Day MA$13.22
50-Day MA$14.15
200-Day MA$14.90
See more pivots

Spero Therapeutics Inc Stock, NASDAQ:SPRO

675 Massachusetts Avenue, 14th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.242.1600
Number of Employees: 89

Description

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.